TYLENOL WITH CODEINE NO. 4 TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

ACETAMINOPHEN; CODEINE PHOSPHATE

Beszerezhető a:

JANSSEN INC

ATC-kód:

N02AJ06

INN (nemzetközi neve):

CODEINE AND PARACETAMOL

Adagolás:

300MG; 60MG

Gyógyszerészeti forma:

TABLET

Összetétel:

ACETAMINOPHEN 300MG; CODEINE PHOSPHATE 60MG

Az alkalmazás módja:

ORAL

db csomag:

100

Recept típusa:

Narcotic (CDSA I)

Terápiás terület:

OPIATE AGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0211376001; AHFS:

Engedélyezési státusz:

CANCELLED POST MARKET

Engedély dátuma:

2020-09-25

Termékjellemzők

_~db5_O57037c1db3eb487b8c40bf219e186e85.docx _
_ _
_EDMS-RIM-569211 v2.0 _
_ _
_Page 1 of 38 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TYLENOL
® WITH CODEINE NO. 4
300 mg acetaminophen and 60 mg codeine phosphate tablets
acetaminophen and codeine phosphate tablets, USP
Analgesic-Antipyretic
Janssen Inc.
200 Whitehall Drive
Markham, Ontario
L3R 0T5
www.janssen.com/canada
Date of Revision:
December 7, 2021
SUBMISSION CONTROL NO: 258440
All trademarks used under license.
© 2021 Janssen Inc.
_~db5_O57037c1db3eb487b8c40bf219e186e85.docx _
_ _
_EDMS-RIM-569211 v2.0 _
_ _
_Page 2 of 38 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................15
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND STABILITY
..........................................................................................25
SPECIAL HANDLING INSTRUCTIONS
.......................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II